

200711009A

厚生労働科学研究費補助金

創薬基盤推進研究事業

がんの高度専門医療施設において研究用に提供される試料及び情報を統合した
バイオバンク構築と、その実証的活用に基づくがんの分子解析に関する研究
(H19-生物資源-一般-009)

平成19年度 総括研究報告書

主任研究者 金井 弥栄

平成20（2008）年 4月

目 次

I. 総括研究報告

1. がんの高度専門医療施設において研究用に提供される試料及び情報を統合したバイオバンク構築と、その実証的活用に基づくがんの分子解析に関する研究-----3
金井弥栄

II. 分担研究報告

1. がんの高度専門医療施設において研究用に提供される試料及び情報を統合したバイオバンク構築と、その実証的活用に基づくがんの分子解析に関する研究-----8
金井弥栄

III. 研究成果の刊行に関する一覧表-----13

IV. 研究成果の刊行物・別刷-----15

厚生労働科学研究費補助金（創薬基盤推進研究事業）

統括研究報告書

がんの高度専門医療施設において研究用に提供される試料及び情報を統合したバイオバンク構築と、その実証的活用に基づくがんの分子解析に関する研究

(H19-生物資源-一般-009)

主任研究者 金井 弥栄（国立がんセンター研究所病理部長）

研究要旨

本研究は、質の高い診療情報・病理情報が付随した豊富な臨床試料よりなるバイオバンクを実証的に構築し、がん研究の推進に資することを目的とする。バンク構築のノウハウを全国のがん診療連携拠点病院等に提供し、研究資源の標準化に貢献することを目指している。

本年度は、国立がんセンターに、オーム解析に耐える質と量を備え、疾患や病態の多様性に応じて十分数が確保され、説明と同意に基づく倫理性が担保され、質の高い標準化された臨床情報が付随しているバンクを構築するための、基盤を整備した。カタログシステムHos-CanR 2.1バイオバンク版の開発を進め、すでに要請のあったがん診療連携拠点病院へのHos-CanR 2.1バイオバンク版の現行バージョンの無償供与を開始した。バイオバンク事務室を開設し、標準作業手順書を策定した。平成19年度に、病理組織標本3,000検体程度を新規に受け入れる一方で、国立がんセンターの研究者が倫理委員会の承認を得て行う研究のために病理組織標本1,000検体程度を払い出し、データベースを更新した。現在病理組織標本35,000検体程度ならびに血清標本110,000検体程度を、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる品質を保持すべく適切な環境下に保管している。保管試料をゲノム構造異常の網羅的解析等に供し、保管試料が最新のゲノム解析等に耐える質を保持していることを実証した。研究代表者は生物資源研究合同班会議に出席し、厚生科学行政上の要請の把握に努めた。

（室長）

分担研究者氏名・所属機関名及び所属機関における
職名

高上洋一・国立がんセンター中央病院（部長）

吉田輝彦・国立がんセンター研究所（部長）

金井弥栄・国立がんセンター研究所（部長）

A. 研究目的

国立がんセンターで生み出される質の高い診療情報・病理情報が付随した豊富な臨床試料を、研究資源バンクとして基盤整備する。バイオバンク試料を

【以下研究協力者】

古田耕・国立がんセンター中央病院（医長）

西本寛・国立がんセンターがん対策情報センター

用いてゲノム解析等を行い、バンクの活用ががんの予防・診断・治療の標的候補同定に有益であることを実証する。倫理面にも充分留意したバンク構築のノウハウを、全国のがん診療連携拠点病院等に提供し、我が国におけるがんバンクの標準化・ネットワーク化に資することを旨とする。

B. 研究方法

病理組織標本ならびに血清標本の管理情報と院内がん登録情報を匿名化の上統合し、研究目的での使用に提供者の同意が得られていることを確認できる、カタログシステムの開発を進める。

バイオバンク事務室を開設し、実務担当者を雇用し、標準作業手順書を策定して教育する。国立がんセンターに蓄積され、病理組織・血清・院内がん登録情報としてそれぞれ病理部門・臨床検査部門・がん対策情報センターに別々に集積・保管されてきた研究資源を、バイオバンクに移管する。病理組織標本・血清標本を新規に受け入れ、カタログシステムに登録する。バンク保管試料を、倫理委員会の承認を得て研究を行う国立がんセンターの研究者に払い出し、データベースを更新する。現有試料は、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる質を保持すべく適切な環境下に保管する。

保管試料が最新のゲノム・トランスクリプトーム・プロテオーム解析等に利用可能なことを示すため、研究代表者は倫理委員会の承認を得てバンク試料の一部を用いて分子解析を行う。学術的な成果を公表し、バイオバンク活用ががんの診断・予防・治療の革新を目指した研究に資することを実証する。

(倫理面への配慮)

バンク保管試料は、平成19年8月16日改正文部科学省・厚生労働省「疫学研究に関する倫理指針」に従い、国立がんセンター倫理委員会に研究の承認を得て行われる研究にのみ払い出した。実証的分子解析

は、「疫学研究に関する倫理指針」に従い、国立がんセンター倫理委員会に研究の承認を得（課題番号16-33「ヒト多段階発がん過程におけるDNAメチル化の変化に関する研究」研究代表者：金井弥栄）、倫理面に充分配慮して研究を進めた。全ての分子病理解析は、連結可能匿名化し、患者の個人情報保護に充分配慮して進めた。すなわち、個人識別番号と匿名化番号の対応表は、研究所内におかれた匿名管理者によって終始厳重に管理され、診療情報と同時に閲覧されることはなかった。実験室においては、終始患者個人を特定することなく研究を進めた。

C. 研究結果

研究協力者吉田輝彦・西本寛等とともに、バイオバンクカタログシステムHos-CanR 2.1バイオバンク版の開発を進めた。本システムは、がん診療連携拠点病院等全国約500施設に既に無償配布している院内がん登録アプリケーションHos-CanR 2.1に、機能を付加する形で開発した。すでに要請のあったがん診療連携拠点病院への、Hos-CanR 2.1バイオバンク版の現行バージョンの無償供与を開始し、具体的な試料管理方法等についても助言した。平成20年度以降のHos-CanR 2.1バイオバンク版の検証・改良に備え、現在、バンクユーザーである国立がんセンターの研究者に対し、Hos-CanR 2.1バイオバンク版の機能性について評価を求めている。さらに、研究代表者は生物資源研究合同班会議に出席し、厚生科学行政上の要請の把握に努めた。

セキュリティ対策と液体窒素タンク・冷凍冷蔵庫等の設備を備えたバイオバンク事務室を開設し、臨床検査技師の国家資格を有する管理実務担当者を雇用して教育した。バイオバンク事務室運用規程ならびに標準作業手順書を策定した。研究協力者吉田輝彦・高上洋一等とともにバイオバンクの運営にあたった。従来国立がんセンターの病理部門・臨床検査部門に個別に保管され、統一したデータベースで

管理されていなかった病理組織標本33,000検体程度ならびに血清標本110,000検体が、平成19年度にバイオバンクに移管された。平成19年度に、病理組織標本3,000検体程度を新規に受け入れる一方で、国立がんセンターの研究者が倫理委員会の承認を得て行う研究のために病理組織標本1,000検体程度を払い出し、データベースを更新した。血清検体の受け入れには、研究協力者古田耕があたった。バイオバンク現有臨床試料は、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる質を保持すべく適切な環境下に保管している。

研究代表者等は、倫理委員会の承認を得ておこなう諸臓器がんの多段階発生過程におけるゲノム構造異常ならびにDNAメチル化異常の網羅的解析に、バンク試料の一部を供した。バイオバンク保管病理組織標本から抽出した核酸検体が、BACアレイを基盤とする比較ゲノムハイブリダイゼーション (CGH) 法・メチル化CpGアイランド増幅 (BAMCA) 法に供するに十分な質を保持していることを確認した。例えば肝多段階発がんの諸過程に対応する組織標本におけるBAMCA法では、DNAメチル化減弱・亢進を示したBACクローン数は、正常肝組織に比して、前がん状態にあると考えられる慢性肝炎ないし肝硬変症を呈する非がん肝組織で既に有意に増加しており、肝細胞がん組織でさらに有意に増加していた。正常肝組織と前がん状態にある肝組織を区別し得るDNAメチル化減弱・亢進を示し、かつその変化が肝細胞がんに進展するまで受け継がれるBACクローンを抽出し得た。肝細胞がんの分化度・門脈侵襲の有無・肝内転移の有無と有意に相関するDNAメチル化減弱・亢進を示す、BACクローンを抽出し得た。

D. 考察

ゲノム規模のDNAメチル化異常は、前がん状態から肝細胞がんの悪性進展に至るまで、肝多段階発がん過程に寄与する可能性があると考えられた。バンク

試料を用いた実証的分子解析の結果から、バンク保管組織標本から抽出した核酸検体が、最新のオーム解析に耐える質を保持していることが分かった。バイオバンク保管試料を用いた解析が、発がんリスク診断・がんの個性診断ツールの開発の基盤となる可能性が示された。今後長期にわたって試料を研究に用いることができるよう、データベースを遅滞なく更新し、試料を引き続き適切に管理することが重要と考えられた。

E. 結論

今後、カタログシステムHos-CanR 2.1バイオバンク版の検証と改善・必要な機能の追加を、バンクユーザーである国立がんセンターの研究者の評価を反映させつつ、随時継続して行う必要がある。特に、腫瘍単位である院内がん登録のデータを患者個人単位に整理し、複数の試料採取ポイントと関連付けるシステムを構築する必要がある。保管試料が分子解析に利用可能なことを更に広く示すため、実証的分子解析を最新の手技を取り入れて発展させる予定である。将来のネットワーク化を見据えて、Hos-CanR 2.1バイオバンク版のがん診療連携拠点病院等への無償配布を継続する一方で、全国のがん診療連携拠点病院間等での研究資源のネットワーク化の可能性を探る。今後は、産学官の外部機関の研究者から国立がんセンターの研究者に共同研究の求めがある場合、倫理委員会の承認を得て匿名化した試料を外部研究者に提供し、広く我が国のがん研究の発展に寄与することを目指す。

F. 健康危険情報

該当なし

G. 研究発表

1. 論文発表

Kanai, Y. Overexpression of HDACs: a prognostic

- marker for gastric cancer identified by tissue microarray. *Lancet Oncol*, 9: 91-93, 2008.
- Kanai, Y., and Hirohashi, S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. *Carcinogenesis*, 28: 2434-2442, 2007.
- Sawada, M., Kanai, Y., Arai, E., Ushijima, S., Ojima, H., and Hirohashi, S. Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. *Cancer Lett*, 251: 211-219, 2007.
- Kikuchi, R., Tsuda, H., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., and Imoto, I. Connective Tissue Growth Factor is a putative conditional tumor-suppressor gene frequently inactivated by promoter hypermethylation in ovarian cancer. *Cancer Res*, 67: 7095-7105, 2007.
- Loukopoulos, P., Shibata, T., Katoh, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., and Hirohashi, S. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. *Cancer Sci*, 98: 392-400, 2007.
- Kobayashi, N., Hiraoka, N., Yamagami, W., Ojima, H., Kanai, Y., Kosuge, T., Nakajima, A., and Hirohashi, S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. *Clin Cancer Res*, 13: 902-911, 2007.
- Takahashi, Y., Akishima-Fukasawa, Y., Kobayashi, N., Sano, T., Kosuge, T., Nimura, Y., Kanai, Y., and Hiraoka, N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. *Clin Cancer Res*, 13: 187-196, 2007.
- Miyake, M., Sugano, K., Kawashima, K., Ichikawa, H., Hirabayashi, K., Kodama, T., Fujimoto, H., Kakizoe, T., Kanai, Y., Fujimoto, K., and Hirao, Y. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. *Biochem Biophys Res Commun*, 362: 865-871, 2007.
- Yoshida Y, Kokubu A, Suzuki K, Kuribayashi H, Tsuta K, Matsuno Y, Kusumoto M, Kanai Y, Asamura H, Hirohashi S, and Shibata T. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. *Jpn J Clin Oncol*, 37: 907-912, 2007.
2. 学会発表
- 新井恵吏, 金井弥栄, 牛島抄織, 藤元博行, 細田文恵, 柴田龍弘, 近藤格, 横井佐奈, 井本逸勢, 稲澤譲治, 広橋説雄. 腎がんの発生過程におけるDNAメチル化の変化のゲノム網羅的解析. 第1回日本エピジェネティクス研究会年会 2007年6月
- 金井弥栄. 慢性肝炎・肝硬変症・肝細胞がんにおけるDNAメチル化異常. 第4回日本病理学会カンファレンス「肝疾患研究の最前線: 現状と課題」 2007年7月
- 新井恵吏, 金井弥栄, 牛島抄織, 尾島英知, 細田文恵, 柴田龍弘, 近藤格, 横井佐奈, 井本逸勢, 稲澤譲治, 広橋説雄. 肝多段階発がん過程におけるDNAメチル化の変化のゲノム網羅的解析. 第4回日本病理学会カンファレンス 2007年7月
- Arai E, Kanai Y, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, and Hirohashi S. Genetic classification of renal cell carcinoma associated with DNA

methylation alteration and prognosis of patients. 66th Annual Meeting of the Japanese Cancer Association (第66回日本癌学会学術総会) 2007年10月

Kikuchi R, Imoto I, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, and Inazawa J. CTGF is a tumor-suppressor gene frequently inactivated by promoter hypermethylation in ovarian cancer. 66th Annual Meeting of the Japanese Cancer Association (第66回日本癌学会学術総会) 2007年10月

Satow R, Shitashige M, Honda K, Kanai Y, Hirohashi S, and Yamada T. Whole-genome exon-level transcriptome survey of human hepatocellular carcinoma. 66th Annual Meeting of the Japanese Cancer Association (第66回日本癌学会学術総会) 2007年10月

H. 知的財産権の出願・登録状況

該当なし

厚生労働科学研究費補助金（創薬基盤推進研究事業）

分担研究報告書

がんの高度専門医療施設において研究用に提供される試料及び情報を統合したバイオバンク構築と、その実証的活用に基づくがんの分子解析に関する研究
(H19-生物資源-一般-009)

分担研究者 金井 弥栄（国立がんセンター研究所病理部長）

研究要旨

本研究は、質の高い診療情報・病理情報が付随した豊富な臨床試料よりなるバイオバンクを実証的に構築し、がん研究の推進に資することを目的とする。バンク構築のノウハウを全国のがん診療連携拠点病院等に提供し、研究資源の標準化に貢献することを目指している。

本年度は、国立がんセンターに、オーム解析に耐える質と量を備え、疾患や病態の多様性に応じて十分数が確保され、説明と同意に基づく倫理性が担保され、質の高い標準化された臨床情報が付随しているバンクを構築するための、基盤を整備した。カタログシステムHos-CanR 2.1バイオバンク版の開発を進め、すでに要請のあったがん診療連携拠点病院へのHos-CanR 2.1バイオバンク版の現行バージョンの無償供与を開始した。バイオバンク事務室を開設し、標準作業手順書を策定した。平成19年度に、病理組織標本3,000検体程度を新規に受け入れる一方で、国立がんセンターの研究者が倫理委員会の承認を得て行う研究のために病理組織標本1,000検体程度を払い出し、データベースを更新した。現在病理組織標本35,000検体程度ならびに血清標本110,000検体程度を、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる品質を保持すべく適切な環境下に保管している。保管試料をゲノム構造異常の網羅的解析等に供し、保管試料が最新のゲノム解析等に耐える質を保持していることを実証した。生物資源研究合同班会議に出席し、厚生科学行政上の要請の把握に努めた。

A. 研究目的

国立がんセンターで生み出される質の高い診療情報・病理情報が付随した豊富な臨床試料を、研究資源バンクとして基盤整備する。バイオバンク試料を用いてゲノム解析等を行い、バンクの活用ががんの予防・診断・治療の標的候補同定に有益であること

を実証する。倫理面にも充分留意したバンク構築のノウハウを、全国のがん診療連携拠点病院等に提供し、我が国におけるがんバンクの標準化・ネットワーク化に資することを目指す。

B. 研究方法

病理組織標本ならびに血清標本の管理情報と院内

がん登録情報を匿名化の上統合し、研究目的での使用に提供者の同意が得られていることを確認できる、カタログシステムの開発を進める

バイオバンク事務室を開設し、実務担当者を雇用し、標準作業手順書を策定して教育する。国立がんセンターに蓄積され、病理組織・血清・院内がん登録情報としてそれぞれ病理部門・臨床検査部門・予防検診研究センターに別々に集積・保管されてきた研究資源を、バイオバンクに移管する。病理組織標本・血清標本を新規に受け入れ、カタログシステムに登録する。バンク保管試料を、倫理委員会の承認を得て研究を行う国立がんセンターの研究者に払い出し、データベースを更新する。現有試料は、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる質を保持すべく適切な環境下に保管する。

保管試料が最新のゲノム・トランスクリプトーム・プロテオーム解析等に利用可能なことを示すため、研究代表者は倫理委員会の承認を得てバンク試料の一部を用いて分子解析を行う。学術的な成果を公表し、バイオバンク活用ががんの診断・予防・治療の革新を目指した研究に資することを実証する。

(倫理面への配慮)

バンク保管試料は、平成19年8月16日改正文部科学省・厚生労働省「疫学研究に関する倫理指針」に従い、国立がんセンター倫理委員会に研究の承認を得て行われる研究にのみ払い出した。実証的分子解析は、「疫学研究に関する倫理指針」に従い、国立がんセンター倫理委員会に研究の承認を得（課題番号16-33「ヒト多段階発がん過程におけるDNAメチル化の変化に関する研究」研究代表者：金井弥栄）、倫理面に充分配慮して研究を進めた。全ての分子病理解析は、連結可能匿名化し、患者の個人情報保護に充分配慮して進めた。すなわち、個人識別番号と匿名化番号の対応表は、研究所内におかれた匿名管理者によって終始厳重に管理され、診療情報と

同時に閲覧されることはなかった。実験室においては、終始患者個人を特定することなく研究を進めた。

C. 研究結果

バイオバンクカタログシステムHos-CanR 2.1バイオバンク版の開発を進めた。本システムは、がん診療連携拠点病院等全国約500施設に既に無償配布している院内がん登録アプリケーションHos-CanR 2.1に、機能を付加する形で開発した。すでに要請のあったがん診療連携拠点病院への、Hos-CanR 2.1バイオバンク版の現行バージョンの無償供与を開始し、具体的な試料管理方法等についても助言した。平成20年度以降のHos-CanR 2.1バイオバンク版の検証・改良に備え、現在、バンクユーザーである国立がんセンターの研究者に対し、Hos-CanR 2.1バイオバンク版の機能性について評価を求めている。さらに、生物資源研究合同班会議に出席し、厚生科学行政上の要請の把握に努めた。

セキュリティ対策と液体窒素タンク・冷凍冷蔵庫等の設備を備えたバイオバンク事務室を開設し、臨床検査技師の国家資格を有する管理実務担当者を雇用して教育した。バイオバンク事務室運用規程ならびに標準作業手順書を策定した。従来国立がんセンターの病理部門・臨床検査部門に個別に保管され、統一したデータベースで管理されていなかった病理組織標本33,000検体程度ならびに血清標本110,000検体が、平成19年度にバイオバンクに移管された。平成19年度に、病理組織標本3,000検体程度を新規に受け入れる一方で、国立がんセンターの研究者が倫理委員会の承認を得て行う研究のために病理組織標本1,000検体程度を払い出し、データベースを更新した。バイオバンク現有臨床試料は、核酸・蛋白等の変性を防ぎ直ちに研究の用に供せる質を保持すべく適切な環境下に保管している。

倫理委員会の承認を得ておこなう諸臓器がんの多段階発生過程におけるゲノム構造異常ならびにDNA

メチル化異常の網羅的解析に、バンク試料の一部を供した。バイオバンク保管病理組織標本から抽出した核酸検体が、BACアレイを基盤とする比較ゲノムハイブリダイゼーション (CGH) 法・メチル化CpGアイランド増幅 (BAMCA) 法に供するに十分な質を保持していることを確認した。例えば肝多段階発がんの諸過程に対応する組織標本におけるBAMCA法では、DNAメチル化減弱・亢進を示したBACクローン数は、正常肝組織に比して、前がん状態にあると考えられる慢性肝炎ないし肝硬変症を呈する非がん肝組織で既に有意に増加しており、肝細胞がん組織でさらに有意に増加していた。正常肝組織と前がん状態にある肝組織を区別し得るDNAメチル化減弱・亢進を示し、かつその変化が肝細胞がんに進展するまで受け継がれるBACクローンを抽出し得た。肝細胞がんの分化度・門脈侵襲の有無・肝内転移の有無と有意に相関するDNAメチル化減弱・亢進を示す、BACクローンを抽出し得た。

D. 考察

ゲノム規模のDNAメチル化異常は、前がん状態から肝細胞がんの悪性進展に至るまで、肝多段階発がん過程に寄与する可能性があると考えられた。バンク試料を用いた実証的分子解析の結果から、バンク保管組織標本から抽出した核酸検体が、最新のオーム解析に耐える質を保持していることが分かった。バイオバンク保管試料を用いた解析が、発がんリスク診断・がんの個性診断ツールの開発の基盤となる可能性が示された。今後長期にわたって試料を研究に用いることができるよう、データベースを遅滞なく更新し、試料を引き続き適切に管理することが重要と考えられた。

E. 結論

今後、カタログシステムHos-CanR 2.1バイオバンク版の検証と改善・必要な機能の追加を、バンクユ

ーザーである国立がんセンターの研究者の評価を反映させつつ、随時継続して行う必要がある。特に、腫瘍単位である院内がん登録のデータを患者個人単位の整理し、複数の試料採取ポイントと関連付けるシステムを構築する必要がある。保管試料が分子解析に利用可能なことを更に広く示すため、実証的分子解析を最新の手技を取り入れて発展させる予定である。将来のネットワーク化を見据えて、Hos-CanR 2.1バイオバンク版のがん診療連携拠点病院等への無償配布を継続する一方で、全国のがん診療連携拠点病院間等での研究資源のネットワーク化の可能性を探る。今後は、産学官の外部機関の研究者から国立がんセンターの研究者に共同研究の求めがある場合、倫理委員会の承認を得て匿名化した試料を外部研究者に提供し、広く我が国のがん研究の発展に寄与することを目指す。

F. 健康危険情報

該当なし

G. 研究発表

1. 論文発表

Kanai, Y. Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray. *Lancet Oncol*, 9: 91-93, 2008.

Kanai, Y., and Hirohashi, S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. *Carcinogenesis*, 28: 2434-2442, 2007.

Sawada, M., Kanai, Y., Arai, E., Ushijima, S., Ojima, H., and Hirohashi, S. Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. *Cancer Lett*, 251: 211-219, 2007.

Kikuchi, R., Tsuda, H., Kanai, Y., Kasamatsu, T.,

- Sengoku, K., Hirohashi, S., Inazawa, J., and Imoto, I. Connective Tissue Growth Factor is a putative conditional tumor-suppressor gene frequently inactivated by promoter hypermethylation in ovarian cancer. *Cancer Res*, 67: 7095-7105, 2007.
- Loukopoulos, P., Shibata, T., Kato, H., Kokubu, A., Sakamoto, M., Yamazaki, K., Kosuge, T., Kanai, Y., Hosoda, F., Imoto, I., Ohki, M., Inazawa, J., and Hirohashi, S. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. *Cancer Sci*, 98: 392-400, 2007.
- Kobayashi, N., Hiraoka, N., Yamagami, W., Ojima, H., Kanai, Y., Kosuge, T., Nakajima, A., and Hirohashi, S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. *Clin Cancer Res*, 13: 902-911, 2007.
- Takahashi, Y., Akishima-Fukasawa, Y., Kobayashi, N., Sano, T., Kosuge, T., Nimura, Y., Kanai, Y., and Hiraoka, N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. *Clin Cancer Res*, 13: 187-196, 2007.
- Miyake, M., Sugano, K., Kawashima, K., Ichikawa, H., Hirabayashi, K., Kodama, T., Fujimoto, H., Kakizoe, T., Kanai, Y., Fujimoto, K., and Hirao, Y. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. *Biochem Biophys Res Commun*, 362: 865-871, 2007.
- Yoshida Y, Kokubu A, Suzuki K, Kuribayashi H, Tsuta K, Matsuno Y, Kusumoto M, Kanai Y, Asamura H, Hirohashi S, and Shibata T. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. *Jpn J Clin Oncol*, 37: 907-912, 2007.
2. 学会発表
- 新井恵吏, 金井弥栄, 牛島抄織, 藤元博行, 細田文恵, 柴田龍弘, 近藤格, 横井佐奈, 井本逸勢, 稲澤譲治, 広橋説雄. 腎がんの発生過程におけるDNAメチル化の変化のゲノム網羅的解析. 第1回日本エピジェネティクス研究会年会 2007年6月
- 金井弥栄. 慢性肝炎・肝硬変症・肝細胞がんにおけるDNAメチル化異常. 第4回日本病理学会カンファレンス「肝疾患研究の最前線: 現状と課題」 2007年7月
- 新井恵吏, 金井弥栄, 牛島抄織, 尾島英知, 細田文恵, 柴田龍弘, 近藤格, 横井佐奈, 井本逸勢, 稲澤譲治, 広橋説雄. 肝多段階発がん過程におけるDNAメチル化の変化のゲノム網羅的解析. 第4回日本病理学会カンファレンス 2007年7月
- Arai E, Kanai Y, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, and Hirohashi S. Genetic classification of renal cell carcinoma associated with DNA methylation alteration and prognosis of patients. 66th Annual Meeting of the Japanese Cancer Association (第66回日本癌学会学術総会) 2007年10月
- Kikuchi R, Imoto I, Tsuda H, Kanai Y, Kasamatsu T, Sengoku K, Hirohashi S, and Inazawa J. CTGF is a tumor-suppressor gene frequently inactivated by promoter hypermethylation in ovarian cancer. 66th Annual Meeting of the Japanese Cancer Association (第66回日本癌学会学術総会) 2007年10月
- Satow R, Shitashige M, Honda K, Kanai Y, Hirohashi S, and Yamada T. Whole-genome

exon-level transcriptome survey of human
hepatocellular carcinoma. 66th Annual
Meeting of the Japanese Cancer Association
(第66回日本癌学会学術総会) 2007年10月

H. 知的財産権の出願・登録状況

該当なし

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Kanai, Y.</u>	Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray.	Lancet Oncol	9 (2)	91-93	2008
<u>Kanai, Y.</u> , et al.	Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state.	Carcinogenesis	28 (12)	2434-2442	2007
Sawada, M., <u>Kanai, Y.</u> , et al.	Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion.	Cancer Lett	251 (2)	211-219	2007
Kikuchi, R., <u>Kanai, Y.</u> , et al.	Connective Tissue Growth Factor is a putative conditional tumor-suppressor gene frequently inactivated by promoter hypermethylation in ovarian cancer.	Cancer Res	67 (15)	7095-7105	2007
Loukopoulos, P., <u>Kanai, Y.</u> , et al.	Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome.	Cancer Sci	98 (3)	392-400	2007
Kobayashi, N., <u>Kanai, Y.</u> , et al.	Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors.	Clin Cancer Res	13 (3)	902-911	2007
Takahashi, Y., <u>Kanai, Y.</u> , et al.	Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors.	Clin Cancer Res	13 (1)	187-196	2007
Miyake, M., <u>Kanai, Y.</u> , et al.	Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.	Biochem Biophys Res Commun	362 (4)	865-871	2007

Yoshida Y, <u>Kanai Y.</u> , et al.	Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-grass opacity.	Jpn J Clin Oncol	37 (12)	907-912	2007
--	---	------------------	---------	---------	------

help to decrease the high percentage of missing values. Second, studies should ensure that standard methods and antibodies to assess CA 19-9 concentration are used and should report survival according to different baseline CA 19-9 concentrations. These measures will allow appropriate comparisons of different studies and practical conclusions to be drawn to enable appropriate patient stratification in future phase III trials.

Gianpaolo Balzano, *Valerio Di Carlo

Pancreas Unit, Department of Surgery, San Raffaele Scientific Institute, Milan, Italy
dicarlo.valerio@hsr.it

The authors declared no conflicts of interest

1 Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EURO CARE-4 study. *Lancet Oncol* 2007; **8**: 773-83.

- 2 Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modelled period analysis. *J Clin Oncol* 2007; **25**: 3274-80.
- 3 Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. *Oncology* 2006; **70**: 255-64.
- 4 Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. *Br J Cancer* 1994; **69**: 515-19.
- 5 Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J Clin Oncol* 2005; **23**: 3509-16.
- 6 Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. *Br J Cancer* 2005; **93**: 740-43.
- 7 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. *Br J Cancer* 2005; **93**: 195-99.
- 8 Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour marker response to chemotherapy in patients with advanced pancreatic cancer treated in a randomized controlled trial. *Lancet Oncol* 2008; **9**: 132-38.

Overexpression of HDACs: a prognostic marker for gastric cancer identified by tissue microarray

Acetylation and deacetylation of histones have important roles in transcriptional regulation in eukaryotic cells.¹ The acetylation status of histones is decided by the activity of histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs acetylate the ϵ -amino group of lysine residues on histones, thereby neutralising their positive charge and diminishing their ability to bind negatively charged DNA. An open chromatin configuration provides accessibility for transcription factors. Cross-talk between histone acetylation or methylation and DNA methylation has profound implications for gene expression. HDACs remove the acetyl groups, thereby allowing compacted chromatin to reform. So far, 18 HDAC isoforms have been identified and classified based on homology with yeast HDACs. HDACs also have many non-histone protein substrates, such as transcription factors and signal transduction mediators.

Histone acetylation is, along with DNA methylation, one of the most consistent epigenetic mechanisms of multistage human carcinogenesis.² Histone hypoacetylation affects the expression of genes involved in uncontrolled cell growth, differentiation, and apoptosis. The p21 gene is one of the best-studied targets of histone hypoacetylation in human cancers. In gastric

cancer, overexpression at the mRNA and protein levels of HDAC isoform 1³ has been reported in 25 samples of gastric-cancer tissue and in 71 samples of gastric-cancer tissue for HDAC isoform 2.⁴ However, to my knowledge, there have been no published systematic reports about the expression levels of HDACs in large series of patients with gastric cancer.

In this issue of *The Lancet Oncology*, Weichert and colleagues⁵ report an immunohistochemical study of the expression levels of HDAC isoforms 1, 2, and 3 in two cohorts of patients with gastric cancer (143 patients in a training group and 150 patients in a validation group). Initially, nuclear staining of HDACs in cancer cells was scored according to staining intensity and percentage of immunoreactive cells. After several grouping algorithms were tested, the simplest cut-off values were chosen for reproducibility, since clinicopathological and survival correlations were fairly robust. This system showed that concurrent overexpression of HDACs and overexpression of HDAC2 were significantly correlated with lymph-node metastasis and shorter survival. Immunohistochemical assessment of HDACs might therefore be of substantial prognostic value for gastric cancer, although the present system should be validated in appropriate prospective studies.

See [Articles](#) page 139




Figure: Tissue microarray block including a cylindrical core from a gastric cancer
 (A) Macroscopic view of an advanced gastric cancer (arrowheads) in a distal gastrectomy specimen. (B) Histological heterogeneity is evident in a routine histological slide. WDAC=well-differentiated adenocarcinoma component. PDAC=poorly differentiated adenocarcinoma component. IF=invading front. VI=venous involvement. Haematoxylin-eosin staining. (C) A cylindrical core represents only some of the characteristics of this tumour. Haematoxylin-eosin staining. Construction of tissue microarray was approved by the Ethics Committee of the National Cancer Center, Tokyo, Japan. Photos courtesy of Yukihiro Nakanishi, Pathology Division, National Cancer Center Research Institute, Tokyo, Japan.

HDAC inhibitors induce the expression of p21 and other cell-cycle regulators, pro-apoptotic proteins such as Bax and Bad, and repress the expression of metastasis-promoting proteins, such as matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), and pro-angiogenic factors such as vascular endothelial growth factor.⁶ Healthy cells are relatively more resistant to HDAC-inhibitor-induced cell death. Therefore, HDAC inhibitors might be promising new anticancer drugs,

and many are currently being tested in phase I or II clinical trials. After appropriate validation, the present data obtained by Weichert and co-workers might help to predict therapeutic responses to HDAC inhibitors in patients with gastric cancer.


The immunohistochemical assessment system was established by Weichert's group with the use of tissue microarray. This technique allows rapid visualisation of molecular targets in thousands of tissue specimens at a time, and at the DNA, RNA, or protein level. Unlike methods that use conventional time-consuming molecular pathology, high-throughput molecular profiling of cancers by use of tissue microarray might be advantageous for screening diagnostic and treatment targets.^{8,9} However, each cylindrical core constitutes only a very small portion of a tumour (figure), and thus carries only a small amount of molecular information. Weichert and colleagues took multiple cores from each tumour, and the cut-off values obtained from tissue microarray were validated in a large set of routine histological slides. This type of careful approach is strongly recommended when screening molecular targets using tissue microarray.

However, in spite of such careful validation, the success of screening with the use of tissue microarray might be restricted if immunoreactivity varies substantially in a tumour. Cancers frequently show histological heterogeneity—eg, well-differentiated and poorly differentiated components might be present simultaneously in a single tumour. During microscopic assessment of routine histological slides, some candidate target molecules show differences in immunohistochemical staining intensity or subcellular localisation between the well-differentiated and poorly differentiated components, or between the intraepithelial region and the invading front, even in a single tumour.^{10,11} Such heterogeneity in staining patterns, which can be easily overlooked in tissue microarray studies, evokes speculation about the function of the candidate molecule and its participation in multistage carcinogenesis. Not only the efficiency of tissue microarray, but the abundant information obtained from routine histological slides will be of utmost importance in cancer research.

Yae Kanai
 Pathology Division, National Cancer Center Research Institute,
 Tokyo, Japan
 ykanai@ncc.go.jp

The author declared no conflicts of interest.

- 1 Glozak MA, Seto E. Histone deacetylases and cancer. *Oncogene* 2007; **26**: 5420–32.
- 2 Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. *Nat Rev Drug Discov* 2006; **5**: 37–50.
- 3 Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. *Jpn J Cancer Res* 2001; **92**: 1300–04.
- 4 Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. *APMIS* 2005; **113**: 264–68.
- 5 Weichert W, Röske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. *Lancet Oncol* 2008; **9**: 139–48.
- 6 Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. *Clin Exp Metastasis* 2007; published online Dec 5, 2007. DOI:10.1007/s10585-007-9131-5.
- 7 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. *Oncogene* 2007; **26**: 5541–52.
- 8 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med* 1998; **4**: 844–47.
- 9 Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. *Hum Mol Genet* 2001; **10**: 657–62.
- 10 Nakagawa T, Kanai Y, Saito Y, Kitamura T, Kakizoe T, Hirohashi S. Increased DNA methyltransferase 1 protein expression in human transitional cell carcinoma of the bladder. *J Urol* 2003; **170**: 2463–66.
- 11 Peng DF, Kanai Y, Sawada M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. *Cancer Sci* 2005; **96**: 403–08.



If you would like to respond to an article published in *The Lancet Oncology*, please submit your correspondence online at: <http://ees.elsevier.com/thelancetoncology>

Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state

Yae Kanai* and Setsuo Hirohashi

Pathology Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

*To whom correspondence should be addressed. Tel: +81 3 3542 2511;
Fax: +81 3 3248 2463;
Email: ykanai@ncc.go.jp

Alterations of DNA methylation are one of the most consistent epigenetic changes in human cancers. Human cancers generally show global DNA hypomethylation accompanied by region-specific hypermethylation. Alterations of DNA methylation may result in chromosomal instability as a result of changes in chromatin structure. DNA hypermethylation of CpG islands silences various tumor-related genes. Alterations of DNA methylation are frequently observed in cancers associated with chronic inflammation and/or persistent infection with viruses or other pathogenic microorganisms, such as hepatitis B or C viruses, Epstein–Barr virus, human papillomavirus and *Helicobacter pylori*, or with cigarette smoking. Accumulating evidence suggests that alterations of DNA methylation are involved even in the early and precancerous stages. On the other hand, in patients with cancers, aberrant DNA methylation is significantly associated with poorer tumor differentiation, tumor aggressiveness and poor prognosis. Precancerous conditions showing alterations of DNA methylation may progress rapidly and generate more malignant cancers. DNA methyltransferase (DNMT) 1 over-expression is not a secondary result of increased cell proliferative activity but is significantly correlated with the CpG island methylator phenotype, which is defined as frequent DNA hypermethylation of C-type CpG islands that are usually methylated in a cancer-specific (not age-dependent) manner. Splicing alteration of DNMT3b may result in chromosomal instability through DNA hypomethylation of pericentromeric satellite regions. Alteration of DNA methylation may become an indicator for carcinogenic risk estimation and early diagnosis of cancers and a biological predictor of poor prognosis in patients with cancers. Correction of DNA methylation status may offer a new strategy for prevention and therapy of cancers.

Introduction

In the earlier days of cancer research, stepwise and orderly progression of genetic alterations causing activation of oncogenes and inactivation of tumor suppressor genes was considered to be the molecular framework responsible for multistage carcinogenesis in humans. However, genetic events alone may not explain the entire process of carcinogenesis: only a few genetic alterations are known to be responsible, especially in the earlier, precancerous stages. Moreover, microscopic observation of cancers frequently reveals histological heterogeneity (e.g. well, moderately or poorly differentiated carcinoma components are simultaneously observed even in tissue sections from any single patient), reflecting complexity of the biological characteristics of tumors. In addition to genetic events, epigenetic events such as alterations of DNA methylation, which can be

Abbreviations: CIMP, CpG island methylator phenotype; DNMT, DNA methyltransferase; HCC, hepatocellular carcinoma; LOH, loss of heterozygosity; MBD, methyl-CpG-binding protein; mRNA, messenger RNA; PanIN, pancreatic intra-epithelial neoplasia; PCR, polymerase chain reaction; PCNA, proliferating cell nuclear antigen; RCC, renal cell carcinoma; STAT, signal transducer and activator of transcription; TCC, transitional cell carcinoma.

reversible and underlie the histological heterogeneity of cancers, are another leading player in multistage carcinogenesis.

DNA methylation, a covalent chemical modification resulting in addition of a methyl (CH₃) group at the carbon 5 position of the cytosine ring in CpG dinucleotides, plays important roles in chromatin structure modulation, transcriptional regulation and genomic stability, and is essential for the development of mammals (1). The C-terminal catalytic domain of DNA methyltransferases (DNMTs), the major and best known of which is DNMT1, transfers methyl groups from S-adenosylmethionine to cytosines (2). DNMT1's preference for hemimethylated over unmethylated substrates *in vitro* and its targeting of replication foci are believed to allow copying of the methylation pattern of the parental strand to the newly synthesized daughter DNA strand (3). Thus, DNMT1 has been recognized as the 'maintenance' DNMT. DNMT1 can interact with the DNMT1-associated protein 1, histone deacetylase 1 and 2 and Rb and can repress gene transcription (4–6). Since DNMT1^{-/-} embryonic stem cells are able to methylate viral DNA *de novo* (7), independently encoded DNMTs have been sought. Among the subsequently identified DNMTs 2 (8), 3a and 3b (9), DNMT activity of DNMT2 has never been demonstrated (10), whereas DNMT3a and DNMT3b do show *de novo* DNA methylation activity *in vitro* (11).

In comparison with normal cells, human cancer cells show a drastic change in DNA methylation status, generally exhibiting global DNA hypomethylation as well as accompanying region-specific hypermethylation (12,13). As 5-methylcytosine is deaminated to thymine, DNA hypermethylation facilitates gene mutation in human cancers. DNA methylation normally promotes a highly condensed chromatin structure through recruitment of DNA-organizing proteins, and DNA hypomethylation in cancer cells causes chromatin decondensation and chromosomal rearrangements that may result in chromosomal instability. Moreover, DNA hypermethylation of CpG islands near gene-regulatory regions silences specific genes, in cooperation with histone modification, including tumor suppressor genes (14).

Association of DNA methylation alterations with both the precancerous stage and malignant progression

In general, candidate tumor suppressor genes, which are located in the commonly deleted chromosomal regions revealed by genomic structural analysis in human cancers, are frequently silenced by alternative two-hit mechanisms consisting of loss of heterozygosity (LOH) and DNA hypermethylation, rather than gene mutation. Thus, DNA hypermethylation of some chromosomal loci is frequently associated with LOH at the same chromosomal loci in human cancers. LOH on chromosome 16 has been frequently detected by classical restriction fragment length polymorphism analysis using Southern blotting in hepatocellular carcinomas (HCCs) which are poorly differentiated, large in size and associated with metastasis (15). Therefore, LOH on chromosome 16 seems to be a late event during multistage hepatocarcinogenesis. At the time of these discoveries, only a few molecular events in the earlier stage of hepatocarcinogenesis were known. Therefore, we first examined DNA methylation status on chromosome 16 in surgically resected tissue specimens.

Classical Southern blotting showed that the digestion patterns obtained using HpaII, a DNA methylation-sensitive restriction enzyme, were similar to those obtained using MspI, a DNA methylation non-sensitive restriction enzyme, at the D16S32 (16 pter to p13), TAT (16q22.2) and D16S7 (16q24.3) loci in normal liver tissue obtained from patients with liver metastases from primary colon cancer, indicating that genomic DNA is normally unmethylated in these regions. Surprisingly, DNA hypermethylation at the D16S32, TAT and D16S7 loci, compared with normal liver tissues, was frequently

detected even in non-cancerous liver tissues showing chronic hepatitis or liver cirrhosis, which are widely considered to be precancerous conditions, indicating that alterations of DNA methylation are a very early event during multistage hepatocarcinogenesis (16). This was one of the earliest reports of alterations of DNA methylation in the precancerous stage.

Since the molecular weight of HpaII-digested DNA fragments in HCCs was higher than that in precancerous conditions and the intensity of larger sized bands was increased in HCCs in comparison with precancerous conditions, the numbers of methylated CpG dinucleotides and cells showing DNA hypermethylation may increase progressively as precancerous conditions develop into HCCs. The incidence of DNA hypermethylation at any of the D16S32, TAT or D16S7 loci in progressed HCCs was significantly higher than that in early HCCs and significantly correlated with higher histological grade (16). DNA hypermethylation at any of the D16S32, TAT or D16S7 loci was detected more frequently in HCCs showing associated involvement of the portal vein and intrahepatic metastasis than in HCCs without these features (16). The presence of DNA hypermethylation in both precancerous conditions and progressed HCCs suggests that precancerous conditions with aberrant DNA methylation might generate HCCs rapidly and that the HCCs thus generated might already be at a progressed stage when diagnosed.

Silencing of tumor suppressor genes by DNA hypermethylation

The *E-cadherin* gene is located on 16q22.1 near to the above-mentioned hot spots of both DNA hypermethylation and LOH in HCCs. *E-cadherin* acts as a Ca^{2+} -dependent cell-cell adhesion molecule in the adherens junctions of epithelial cells (17). Interactions between *E-cadherin* and cytoskeletal actin proteins through α - and β -catenins confer stability on the adherens junctions. Cell-cell adhesion determines cell polarity and participates in histogenesis. The mutual adhesiveness of cancer cells is significantly weaker than that of normal cells, and this allows cancer cells to disobey the social order, resulting in destruction of histological architecture, which is a morphological hallmark of malignant tumors (18). In signet-ring cell carcinoma of the stomach (19) and lobular carcinoma of the breast (20), in which cancer cells completely lose their mutual adhesiveness even in the *in situ* carcinoma stage, the *E-cadherin* gene is silenced by a two-hit mechanism comprising LOH and gene mutation. A large kindred study of early-onset, diffuse-type stomach cancers in New Zealand revealed a germ line mutation (21), indicating that the *E-cadherin* gene actually satisfies the criteria for a tumor suppressor gene.

On the other hand, suppression of *E-cadherin* activity is believed to trigger the release of cancer cells from primary cancer nests, resulting in cancer invasion and metastasis. In fact, non-invasive epithelial cells acquired the ability to invade into collagen gels upon addition of antibodies against *E-cadherin* (22) or plasmids encoding *E-cadherin*-specific anti-sense RNA (23). Generally, *E-cadherin* expression is reduced in poorly differentiated cancers that have lost their cell-cell adhesion and show a strong invasive tendency (18). Significant correlations between reduced *E-cadherin* expression and poor prognosis have been reported in patients with cancers (18). In order to clarify the mechanism responsible for regulation of *E-cadherin* expression in cancers, we cloned the promoter region of the human *E-cadherin* gene and demonstrated that it showed DNA methylation in human cancer cell lines lacking *E-cadherin* expression (24). We also observed induction of *E-cadherin* expression after treatment with the DNMT inhibitor 5-azacytidine in such cell lines (24). Thus, following the *RB* and *VHL* genes, the *E-cadherin* gene became the third example of a tumor suppressor gene that is silenced by DNA hypermethylation.

When assessed by Southern blotting analysis, DNA hypermethylation around the promoter region of the *E-cadherin* gene was detected in 46% of examined non-cancerous liver tissues showing chronic hepatitis or cirrhosis and in 67% of examined HCCs (25). Immunohistochemical examination revealed that hepatocytes in normal liver tissues showed strong *E-cadherin* immunoreactivity at their cell-cell borders. We found a significant correlation between DNA hypermethylation around the promoter region and reduced *E-cadherin*

expression in primary HCCs (25). This was the first demonstration of a significant correlation between DNA hypermethylation and reduced expression in clinical tissue samples. Heterogeneous *E-cadherin* expression in non-cancerous liver tissues showing chronic hepatitis or cirrhosis, which is associated with small focal areas of hepatocytes showing only slight *E-cadherin* immunoreactivity and is not observed in normal liver tissues, might be due, at least partly, to DNA hypermethylation (25). DNA hypermethylation around the promoter region, which increases during progression from precancerous conditions to HCCs, may participate in hepatocarcinogenesis through reduction of *E-cadherin* expression, resulting in loss of intercellular adhesiveness and destruction of tissue morphology.

DNA hypermethylation of NotI sites at the D17S5 locus has been detected in various human cancers (26). The *hypermethylated-in-cancer-1* gene at this locus (17q13.3) was the first tumor suppressor gene to be identified in commonly methylated chromosomal loci in human cancers (27); human cancer cells transfected with the *hypermethylated-in-cancer-1* gene grew slowly (27) and mice with germ line disruption of one allele of *Hic1* developed different spontaneous malignant tumors (28). DNA methylation at the D17S5 locus was never detected in normal liver tissues but was detected in 44% of examined non-cancerous liver tissues showing chronic hepatitis or cirrhosis and in 90% of examined HCCs (29). In almost all the paired samples showing DNA hypermethylation, the molecular weight of NotI-digested DNA fragments in HCCs was higher than that in precancerous conditions and the intensity of the larger sized bands was higher in HCCs than in precancerous conditions, indicating that the degree of DNA methylation seems to further increase during progression from a precancerous condition to an HCC (29). The level of hypermethylated-in-cancer-1 messenger RNA (mRNA) expression in non-cancerous liver tissues showing chronic hepatitis or cirrhosis was significantly lower than that in normal liver tissues and was further decreased in HCCs (29).

It is now recognized that numerous tumor-related genes, such as *p16*, *hMLH1*, *BRCA1*, *MGMT*, *GSTP1*, *TIMP-3* and *DAPK-1*, are silenced by regional DNA hypermethylation around their promoter regions in human cancers (14). Several techniques, such as restriction landmark genomic scanning (30), methylation-sensitive representational difference analysis (31) and methylated CpG islands amplification (32), have been developed for cloning genes that are differentially methylated between cancer cells and normal cells (33), and the list of tumor-related genes silenced by DNA hypermethylation is being expanded (14).

Alterations of DNA methylation precede chromosomal instability during multistage carcinogenesis

The hot spot for DNA hypermethylation in HCCs corresponds to a previously reported hot spot of LOH on chromosome 16. It remains to be examined whether alterations of DNA methylation might predispose the locus to allelic loss or whether common or different causes facilitate both alterations of DNA methylation and LOH at certain loci. However, it is at least clear that DNA hypermethylation precedes LOH at the same chromosomal loci during hepatocarcinogenesis: even classical Southern blotting has detected DNA hypermethylation in bulk non-cancerous liver tissues showing chronic hepatitis or cirrhosis, in which LOH has never been detected using the same method (16).

Recently, microdissection techniques and polymerase chain reaction (PCR) using microsatellite markers have been developed for detecting LOH in small numbers of cells from paraffin-embedded tissues. LOH has been reported even in microdissected specimens from non-cancerous lesions, e.g. hyperplastic or dysplastic lesions accompanying non-small cell lung cancers (34) and proliferative lesions adjacent to breast cancers (35). In order to re-examine whether aberrant DNA methylation precedes chromosomal instability during hepatocarcinogenesis, we obtained 308 microdissected specimens and examined LOH and microsatellite instability by PCR using 39 microsatellite markers and DNA methylation status of eight C-type CpG islands that are known to be methylated in a cancer-specific, but not age-dependent, manner, as shown in Table I, by methylation-specific PCR and combined bisulfite restriction enzyme analysis.

Table 1. DNA methylation status on C-type CpG islands in tissue samples of various organs

Tissue samples	The incidence of DNA methylation ^a (%)								References
	CpG islands								
	<i>p16</i>	<i>hMLH1</i>	<i>THBS-1</i>	MINT1	MINT2	MINT12	MINT25	MINT31	
Normal liver tissues	0	0	0	0	0	0	0	0	(36)
Non-cancerous liver tissues obtained from patients with HCCs	15	0	0	10	73	23	0	0	
HCCs	70	0	0	45	85	45	8	65	(37)
Non-cancerous stomach mucosae obtained from patients with stomach cancers	17	14	2	22	1	6	ND	0	
Stomach cancers	22	17	24	37	25	17	ND	10	(38)
Colorectal cancers	23	27	9	23	20	23	20	10	
Normal renal tissues	11	0	0	0	0	11	22	0	(39)
Non-tumorous renal tissues obtained from patients with renal tumors	62	12	29	2	5	10	24	0	
Renal tumors	73	12	43	17	8	17	35	5	(40)
Normal urothelia	0	ND	ND	ND	56	0	25	45	
Urinary bladder cancers	21	ND	ND	ND	76	30	35	79	

MINT, methylated in tumor; ND, not done.

^aAnalyzed by methylation-specific PCR or combined bisulfite restriction enzyme analysis.

In non-cancerous liver tissues showing chronic hepatitis, LOH for at least one marker was found in 20% of informative microdissected specimens, and LOH in at least one microdissected specimen was found in 45% of informative cases (36). In non-cancerous liver tissues showing cirrhosis, LOH for at least one marker was found in 15% of informative microdissected specimens, and LOH in at least one microdissected specimen was found in 40% of informative cases (36). LOH was never detected in normal liver tissues obtained from patients with liver metastases from primary colon cancer and in non-cancerous liver tissue showing no remarkable histological findings from patients with HCCs. Although no degree of DNA methylation of any of the examined CpG islands was ever detected in normal liver tissues obtained from patients with liver metastases from primary colon cancer, DNA hypermethylation was found on at least one CpG island even in 58% of examined microdissected specimens of non-cancerous liver tissue showing no remarkable histological features obtained from patients with HCCs, in which LOH was never detected (36). Thus, aberrant DNA methylation is an earlier event preceding chromosomal instability during hepatocarcinogenesis, even when examined using microdissection techniques (41). The low incidence of microsatellite instability in Japanese patients (42) was compatible with absence of silencing of the *hMLH1* gene by DNA hypermethylation during hepatocarcinogenesis (36).

Etiologic backgrounds of carcinogenesis and regional DNA hypermethylation

Alterations of DNA methylation are frequently associated with carcinogenesis related to chronic inflammation and/or persistent infection with viruses or other pathogenic microorganisms, such as chronic hepatitis associated with hepatitis B virus or hepatitis C virus infection. As mentioned above, alterations of DNA methylation occur even in non-cancerous liver tissues showing no remarkable histological findings obtained from patients with HCCs, i.e. even before inflammation has become histologically obvious. This phenomenon might be at least partly attributable to hepatitis viral infection. Hepatitis B virus DNA is integrated into the cellular genome, and the integrated viral DNA is known to alter the DNA methylation status in several adjacent cellular genes and DNA segments (43). Epstein-Barr virus infection in stomach cancers is significantly associated with marked accumulation of DNA hypermethylation of C-type CpG islands (37). Induction of latent membrane protein 1 of Epstein-Barr virus has been reported to induce DNMT1 over-expression in cultured cancer cells (44). *Helicobacter pylori* infection, another etiologic factor that is believed to be involved in stomach carcinogenesis, has also been

reported to strongly promote regional DNA hypermethylation (45), although the molecular mechanisms by which *H. pylori* infection alters DNA methylation are still unclear and warrant further investigation. Cervical intra-epithelial neoplasia is a precursor lesion for squamous cell carcinoma of the uterine cervix closely associated with human papillomavirus infection. DNMT1 protein expression is increased even in low-grade cervical intra-epithelial neoplasias compared with normal squamous epithelium and further increased in higher-grade cervical intra-epithelial neoplasias and squamous cell carcinomas of the uterine cervix (46). Human papillomavirus-16 E7 protein has been reported to associate directly with DNMT1 and stimulate the methyltransferase activity of DNMT1 *in vitro* (47), and accumulation of DNA hypermethylation on tumor-related genes has also been observed during cervical carcinogenesis (48).

In the same way that HCCs are preceded by chronic hepatitis, ductal carcinomas frequently emerge in pancreases damaged by chronic pancreatitis. Therefore, at least a proportion of peripheral pancreatic duct epithelia with an inflammatory background may be at the precancerous stage. When the DNA methylation status of the *p14*, *p15*, *p16*, *p73*, *APC*, *hMLH1*, *MGMT*, *BRCA1*, *GSTP1*, *TIMP-3*, *CDH1* and *DAPK-1* tumor-related genes was examined, the incidence of DNA hypermethylation of at least one of the genes and the average number of methylated genes were significantly higher in microdissected specimens of peripheral pancreatic duct epithelia with an inflammatory background and in another precancerous lesion, pancreatic intra-epithelial neoplasia (PanIN), compared with that in peripheral pancreatic duct epithelia without an inflammatory background, and was further increased in ductal carcinomas (Figure 1; 50). The *BRCA1*, *APC*, *p16* and *TIMP-3* genes are frequently methylated in ductal carcinomas of the pancreas (50). With respect to inflammation-related carcinogenesis, cytokine interleukin-6 treatment has been reported to induce DNMT1 over-expression in cultured cells (51), though the significance of cytokine signaling in alterations of DNA methylation has never been confirmed in chronic pancreatitis *in vivo*.

Cigarette smoking is another background factor associated with alterations of DNA methylation during multistage carcinogenesis. DNA hypermethylation at the D17S5 locus was observed in 31% of examined non-cancerous lung tissues, which may contain progenitor cells for cancers, obtained from patients with non-small cell lung cancers and in 33% of corresponding non-small cell lung cancers (52). The incidence of DNA hypermethylation at the D17S5 locus was significantly associated with poorer differentiation of lung adenocarcinomas (52). The incidence of DNA hypermethylation in both non-cancerous lung tissues and non-small cell lung cancers of patients